Therapeutic Workshop
HAE: "Who's on First?"
Monday, February 11, 2008
9:30 AM
West Foyer
HAE or Hereditary Angiodema is a very rare and potentially life threatening disease. Patients experience spontaneous episodes of very painful edema (swelling) in various parts of the body that can last for days. Hope for these patients is just around the corner with four different treatment approaches nearing approval within the next two years. How do these treatments compare? Who will be first to market? Who will capture the market?
Moderators
- Alex To, M.D.; Managing Director, Senior Analyst, Biotechnology, Natixis Bleichroeder, Inc.
Panelists
- Jens Schneider-Mergener; Chief Executive Officer, Jerini AG
- Ira N. Kalfus, M.D.; Vice President, Medical Affairs, Lev Pharmaceuticals
- Samir Singh; President, U.S. Operations, Pharming NV
- Timothy Craig, D.O.; Professor of Medicine and Pediatrics, Penn State Hershey Medical Center and College of Medicine
Who's Who
Expert: